Business
Marketing Agreement to Enhance Expansion in the US
Marketing Agreement to Enhance Expansion in the US.
About this update from Cizzle Biotechnology Holdings Plc
[{"type":"text","content":"\n \n \n \n This announcement contains inside information for the purposes of article 7 of EU Regulation 596/2014\n \n \n which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018 (\"UK MAR\")\n \n \n . Upon the publication of this announcement this inside information is now considered to be within the public domain.\n \n \n \n \n \n \n 16 June 2022\n \n \n \n Cizzle Biotechnology Holdings Plc\n \n \n \n \n \n \n \n \n (\"Cizzle Biotechnology\" or the \"Company\")\n \n \n \n \n \n \n Marketing Agreement to Enhance Expansion in the USA\n \n \n \n \n \n \n \n Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has entered into an agreement with the Behnke Group, a Texas-based healthcare consulting firm with decades of experience collaborating with healthcare organizations across the USA and internationally. The relationship will build on Cizzle Biotechnology's announcement on 6 May 2022 that it had signed a heads of terms to partner with CorePath Laboratories (\"CorePath\"), a full service cancer reference laboratory, to develop and offer its proprietary early-stage lung cancer test throughout the USA. The Behnke Group was responsible for identifying and facilitating the Company's deal with CorePath and the agreement with them is designed to enhance Cizzle Biotechnology's expansion into the US markets through the Behnke Group's network of connections in the clinical and healthcare industry.\n \n \n Highlights\n \n \n \n ·\n Agreement signed with\n Behnke Group, USA, to promote, identify and facilitate partnerships for Cizzle Biotechnology with healthcare providers and businesses in the USA.\n \n \n ·\n The Behnke Group to\n establish targeted lead generation campaigns to aid formulating marketing and branding strategies and work with their network of USA based health systems, clinical diagnostic and pharmaceutical companies.\n \n \n ·\n The Behnke Group will work together with CorePath, a\n Clinical Laboratory Improvement Amendments (\"CLIA\") and College of American Pathologists (\"CAP\")\n accredited laboratory, to assist the Company.\n \n \n Background\n \n \n Lung cancer is the leading cause of cancer death in the USA, in part because early-stage lung cancer can be asymptomatic, allowing the disease to progress and resulting in po...